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Summary Phenobarbital (PB) has a reputation for safety, and it is commonly
believed that PB-related increases in serum aminotransferase levels do not indicate
or predict the development of significant chronic liver disease. Here we report of two
adult patients with a long history of epilepsy treated with PB who died suddenly: one
as consequence of cardiac arrest, the other of acute bronchopneumonia. At autopsy,
analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which
consisted of mixed eosinophil and monocyte cells, associated with several foci of
necrosis surrounded by a hard ring of non-specific granulomatous tissue. Inflammatory
reactions of internal and external hepatic biliary ducts were also seen. Our findings
illustrate that PB may be associated with chronic liver damage, which may lead to
more serious and deleterious consequences. For this reason, each clinician should
recognize this entity in the differential diagnosis of PB-related asymptomatic chronic
hepatic enzyme dysfunction.
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Phenobarbital (PB) is the oldest antiepileptic drug in
common use. Although it is now generally thought to* Corresponding author at: Cattedra ed U.O. di Neurologia,
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doi:10.1016/j.seizure.2007.05.008be a second-line therapy, PB is recommended as
first-line treatment for partial and generalized
tonic-clonic seizures in resource-poor countries.1
PB also remains one of the most important antiepi-
leptic drugs even in many developed countries,
because of its many advantages, including reliability
of supply, affordable cost, broad spectrum of action,
and ease of use.2
PB has a reputation for safety, but cognitive
and behavioral side-effects which include impaired. Published by Elsevier Ltd. All rights reserved.
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reasons for great concern.2 In addition, PB may
occasionally make serum aminotransferase levels
increase; but it is commonly believed that these
laboratory changes do not indicate or predict the
development of significant chronic liver disease.3
Nonetheless, the clinical implication of drug-
related hepatotoxicity is its potential to progress
to liver failure.4 Although hepatotoxicity related to
PB seems to be uncommon, its true incidence might
be much higher and more severe than is commonly
thought, because of the difficulty in attributing
even severe cases of hepatocellular injury to
drugs.4
Here we report two cases of chronic liver damage
with a mixed pattern of hepatonecrosis and colan-
gitis related to long-term PB treatment. Both adult
patients had a long history of epilepsy treated with
PB, but the cause of sudden death was related
neither to liver failure nor to epilepsy, but to cardiac
arrest in one patient, and acute bronchopneumonia
in the other.Figure 1 Histologic characteristics of liver specimens of
patient 1. (A) (Hematoxiline and eosin 320). Note the
large area of hepatonecrosis, which is surrounded by a
hard ring of non-specific granulomatous tissue. (B) (Hema-
toxiline and eosin 380). Evidence of colangitis with
inflammatory infiltrates of internal and external hepatic
biliary ducts.Case reports
Patient 1
The patient was a 44-year-old man with no family
history of either epilepsy or febrile convulsions and
normal psychomotor development. At the age of 13
years, he developed sporadic secondarily general-
ized tonic-clonic seizures, which disappeared after
treatment with a combination of PB and phenytoin.
The latter drug was stopped after 1 year, and the
patient remained on monotherapy with PB. Serum
levels had been within normal ranges on repeated
controls over the years. The most recent blood
investigation revealed a moderate elevation of
serum aminotransferase levels but no evidence of
viral hepatitis. There was no history of alcohol abuse
or drug addiction. He was only moderately over-
weight. His brain MRI study showed no obvious
abnormalities. On the day of his sudden death he
was working without any evident clinical problems.
During work, he suddenly fell down with a cardio-
respiratory arrest. The emergency service arrived
within a few minutes, but cardio pulmonary resus-
citation was unsuccessful.
At autopsy, no acute lesions were found. Heart
weighed 320 g, and there were several areas of
myocardial fibrosis. The coronary arteries’ internal
diameter were generally reduced by arteriosclero-
sis ‘‘medio-intimal’’ deposits and some coronary
sub-epicardial vessels presented a lumen reduction
of about 50%. Both lungs were congested andedematous, with interstitial fibrosis and evidence
of alveolar inflammatory infiltrates rich in serum
and serum protein fluid, mixed with granulocytes,
macrophages and erythrocytes.
Analysis of liver parenchyma revealed a rich
portal inflammatory infiltrate, which consisted of
mixed eosinophil and monocyte cells. Importantly,
there were several large macro foci of necrosis
surrounded by a hard ring of non-specific granulo-
matous tissue (Fig. 1A). Inflammatory reactions of
internal and external hepatic biliary ducts were
also seen (Fig. 1B). The necrotic material was
stained for mycetes using Mac Manus, Gomori Groc-
cot, PAS and Alcian bleu but did not show any hypha
or spore of mycetes, such as Candida, Aspergillus or
Actynomices.
Toxicological analysis, made by gas chromato-
graphy (GLC) analysis and confirmed by gas mass
spectrometry analysis (GC—MS), showed therapeu-
tic levels of PB in the blood, urine and bile
(15.4 mg/ml, 9.7 mg/ml and 18.9 mg/ml), respec-
tively, while phenytoin or other toxic substances
were undetectable.
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Figure 2 Histologic characteristics of liver specimens of
patient 2. (Hematoxiline and eosin 240). Note the areas
of hepatonecrosis, which are surrounded by a hard ring of
non-specific granulomatous tissue with some inflamma-
tory infiltrate of mixed lymphocytes and monocyte cells.Patient 2
This was a 40-year-old man with partial epilepsy
that started at the age of 18 years after a meningo-
coccal meningitis infection. His brain MRI study
showed no obvious abnormalities. He was on mono-
therapy with PB with relatively good control of his
seizures. There was no history of alcohol abuse or
drug addiction. Blood investigation ruled out hepa-
titis. He died a few days after the onset of severe
acute bronchopneumonia, despite receiving
immediate and intensive treatment with antibio-
tics.
At autopsy, analysis of liver parenchyma revealed
some areas of hepatonecrosis surrounded by a hard
ring of non-specific granulomatous tissue with some
inflammatory infiltrate of mixed lymphocytes and
monocyte cells (Fig. 2). Toxicological analysis
revealed only therapeutic levels of PB.Discussion
Our findings illustrate that PB may be associated
with chronic liver damage characterized by a mixed
pattern of hepatonecrosis and colangitis, which may
lead to more serious and deleterious conse-
quences.4 The risks of long term PB-treated epilep-
tic patients developing liver necrosis are not as well
described in the literature as they are for pheny-
toin.5 We have identified no definite case reports of
PB-induced chronic liver damage in our search of the
literature. PB has been found to produce acute
hepatonecrosis,6 while chronic liver enzyme
abnormalities associated with PB are attributed to
enzyme induction alone,3 Nonetheless, blood liver
tests have a poor predictive value with respect tohistologic involvement.7 In a retrospective analysis
of post-mortem liver samples, hepatocellular
damage was found in about 50% of patients receiving
long-term anticonvulsant therapy.8 So, although
uncommon, each clinician should recognize this
entity in the differential diagnosis of PB-related
asymptomatic chronic hepatic enzyme dysfunction,
especially if vague symptoms such as nausea, fati-
gue or malaise also occur.3
We are aware of the pitfalls and caveats of
diagnosing the cause of drug-related hepatoxicity,4
but the facts suggest that that PB directly contrib-
uted to produce chronic liver damage in our
patients. First, there was the temporal relationship
to the adverse event as both patients had long-term
exposure to PB. Moreover, thorough clinical and
laboratory investigations excluded other causes of
liver dysfunction, including viral hepatitis or alcohol
abuse. Although patient 1 had also taken phenytoin,
it was only for approximately 1 year at the beginning
of his epilepsy, so it is unlikely that it played a major
role in causing liver damage in that patient.
Although patient 2 had consumed other potentially
harmful medications, including antibiotics, for only
a few days before his death, it cannot be ruled out
definitively that these compounds did not contri-
bute to the liver damage. It should be noted, how-
ever, that in both patients the histologic findings
were highly characteristic of PB hepatotoxicity with
a mixed hepatocellular and concurrent cholestatic
component.4 These pathological features discount
the role of cardiovascular shock, which is known to
produce liver injury,4 as a contributory factor, since
damage to other organs, especially the kidneys,
would be expected in this situation.
Nonetheless, the part played by other factors in
our patients remains unknown, as drug-related
hepatotoxicity cannot be viewed as a single disease,
and many different mechanisms lead to hepatotoxi-
city.4 For instance, genetic polymorphisms have a
strong influence on drug metabolism and may pre-
dispose to drug-induced hepatotoxicity.9 Moreover,
adults are generally more susceptible to hepato-
toxicity than children, while obesity and malnutri-
tion are also susceptibility factors.4 Concomitant
use of antiepileptic drugs that induce microsomal
P450 enzymes, such as PB and phenytoin, may
enhance the production of a toxic metabolite,
and hence increase the risk of hepatotoxicity with
combined therapy.10References
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